Senti Biosciences, Inc. (NASDAQ:SNTI) Given Consensus Recommendation of “Moderate Buy” by Brokerages

Shares of Senti Biosciences, Inc. (NASDAQ:SNTI) have been given a consensus recommendation of “Moderate Buy” by the five research firms that are covering the stock, Marketbeat.com reports. One research analyst has rated the stock with a sell rating, three have issued a buy rating and one has given a strong buy rating to the company. The average 1 year price target among brokerages that have covered the stock in the last year is $9.00.

Several research analysts have weighed in on the company. Chardan Capital boosted their price target on Senti Biosciences from $12.00 to $13.00 and gave the company a “buy” rating in a report on Tuesday, December 9th. Wall Street Zen upgraded Senti Biosciences to a “sell” rating in a report on Saturday, December 13th. Finally, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Senti Biosciences in a research report on Thursday, January 22nd.

Institutional Trading of Senti Biosciences

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Jane Street Group LLC acquired a new position in shares of Senti Biosciences during the 4th quarter valued at about $40,000. Virtu Financial LLC acquired a new stake in shares of Senti Biosciences in the fourth quarter worth approximately $46,000. Citadel Advisors LLC acquired a new stake in shares of Senti Biosciences in the third quarter worth approximately $117,000. Geode Capital Management LLC grew its holdings in Senti Biosciences by 395.6% in the second quarter. Geode Capital Management LLC now owns 147,314 shares of the company’s stock valued at $311,000 after purchasing an additional 117,588 shares during the period. Finally, Armistice Capital LLC purchased a new stake in Senti Biosciences in the second quarter valued at approximately $1,883,000. Hedge funds and other institutional investors own 25.70% of the company’s stock.

Senti Biosciences Stock Performance

Shares of SNTI opened at $0.88 on Thursday. Senti Biosciences has a 1 year low of $0.80 and a 1 year high of $5.10. The company’s 50 day simple moving average is $0.95 and its 200 day simple moving average is $1.39. The company has a market capitalization of $23.16 million, a price-to-earnings ratio of -0.26 and a beta of 2.12.

About Senti Biosciences

Senti Biosciences (NASDAQ:SNTI) is a clinical-stage synthetic biology company focused on engineering next-generation cell therapies. The company’s platform leverages modular genetic circuits to sense disease signals and precisely control cellular functions, with the goal of improving safety and efficacy in oncology and immune-mediated diseases.

Senti’s core technologies include its SENTINEL circuit platform and SNIP receptor system, which enable programmable sensing of molecular cues and context-dependent payload release.